Following a limited submission
AWMSG advice |
|
| Status: Recommended | |
Darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). |
|
Medicine details |
|
| Medicine name | darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza®) |
| Formulation | 800 mg / 150 mg / 200 mg / 10 mg film-coated tablet |
| Reference number | 2418 |
| Indication | Treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Infections |
| Submission type | Limited |
| Status | Recommended |
| Advice number | 0418 |
| NMG meeting date | 10/01/2018 |
| AWMSG meeting date | 14/02/2018 |
| Date of issue | 05/03/2018 |
| Date of last review | March 2021 |